Exploratory identification of predictive biomarkers in randomized trials with normal endpoints

被引:8
|
作者
Krzykalla, Julia [1 ,2 ]
Benner, Axel [1 ]
Kopp-Schneider, Annette [1 ]
机构
[1] German Canc Res Ctr, Div Biostat, Heidelberg, Germany
[2] Heidelberg Univ, Med Fak, Heidelberg, Germany
关键词
individual treatment effect; model-based recursive partitioning; modified covariates; predictive factors; random forests; AMYOTROPHIC-LATERAL-SCLEROSIS; SUBGROUP IDENTIFICATION; VARIABLE SELECTION; RILUZOLE; VALIDATION; TREES;
D O I
10.1002/sim.8452
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
One of the main endeavours in present-day medicine, especially in oncological research, is to provide evidence for individual treatment decisions ("stratified medicine"). In the pursuit of optimal treatment decision rules, the identification of predictive biomarkers that modify the treatment effect is essential. Proposed methods have often been based on recursive partitioning since a wide variety of interaction patterns can be captured automatically and the results are easily interpretable. Furthermore, these methods are readily extendable to high-dimensional settings by means of ensemble learning. In this article, we present predMOB, an adaptation of the model-based recursive partitioning (MOB) for subgroup analysis approach specifically tailored to the identification of predictive factors. In a simulation study, predMOB outperforms the original MOB with respect to the number of false detections and shows to be more robust in moderately complex settings. Furthermore, we compare the results of predMOB for the application to a public data base of amyotrophic lateral sclerosis patients to those obtained from the original MOB and are able to elucidate the nature of the biomarkers' effects.
引用
收藏
页码:923 / 939
页数:17
相关论文
共 50 条
  • [11] Surrogate endpoints in randomized cardiovascular clinical trials
    Domanski, Michael
    Pocock, Stuart
    Bernaud, Corine
    Borer, Jeffrey
    Geller, Nancy
    Revkin, James
    Zannad, Faiez
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 (04) : 411 - 413
  • [12] Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease
    Insel, Philip S.
    Mattsson, Niklas
    Mackin, R. Scott
    Kornak, John
    Nosheny, Rachel
    Tosun-Turgut, Duygu
    Donohue, Michael C.
    Aisen, Paul S.
    Weiner, Michael W.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2015, 2 (05): : 534 - 547
  • [13] Biomarkers as surrogate endpoints in Alzheimer's disease clinical trials
    Kritsidima, M.
    Elferink, A. J.
    Wied, C. C. Gispen-de
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 33 - 33
  • [14] Statistical challenges in the evaluation of surrogate endpoints in randomized trials
    Molenberghs, G
    Buyse, M
    Geys, H
    Renard, D
    Burzykowski, T
    Alonso, A
    CONTROLLED CLINICAL TRIALS, 2002, 23 (06): : 607 - 625
  • [15] Predictive Biomarkers: Identification and Verification
    Yeatman, Timothy J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (17) : 2743 - 2744
  • [16] Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective
    Stephenson, Diane
    Badawy, Reham
    Mathur, Soania
    Tome, Maria
    Rochester, Lynn
    JOURNAL OF PARKINSONS DISEASE, 2021, 11 : S103 - S109
  • [17] A COMPREHENSIVE AND COLLABORATIVE WORKFLOW TO ESTABLISH CUSTOMIZED ENDPOINTS AND BIOMARKERS FOR IMMUNOTHERAPY TRIALS
    Vidal, E. H.
    Mcavoy, D.
    Vallone, A.
    Thomsen, M.
    Maslak, P.
    Harris, A.
    Oved, J.
    Hosszu, K.
    Boelens, J. J.
    CYTOTHERAPY, 2023, 25 (06) : S255 - S255
  • [18] Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines
    Bilusic, Marijo
    Gulley, James L.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (01) : 109 - 117
  • [19] Endpoints for geroscience clinical trials: health outcomes, biomarkers, and biologic age
    Steven R. Cummings
    Stephen B. Kritchevsky
    GeroScience, 2022, 44 : 2925 - 2931
  • [20] Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines
    Marijo Bilusic
    James L. Gulley
    Cancer Immunology, Immunotherapy, 2012, 61 : 109 - 117